Press coverage about Biogen (NASDAQ:BIIB) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biogen earned a news impact score of 0.20 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.3807257887229 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- Biogen (BIIB) Upgraded to Buy at Credit Suisse Group (americanbankingnews.com)
- BRIEF-Biogen Reports Top-Line Results From Phase 2b Study Of Natalizumab In Acute Ischemic Stroke (reuters.com)
- Biogen Halts Tysabri Development in Stroke as Study Fails (finance.yahoo.com)
- Exploring Bioverativ’s Business Profile and Market Presence (finance.yahoo.com)
- Biogen's Tysabri Fails In Stroke Trial — Coming As 'No Surprise' (finance.yahoo.com)
A number of equities analysts have commented on BIIB shares. HC Wainwright reaffirmed a “buy” rating and set a $363.00 price objective (up from $340.00) on shares of Biogen in a research report on Friday, January 26th. Citigroup reissued an “outperform” rating and set a $380.00 target price (up previously from $350.00) on shares of Biogen in a report on Tuesday, January 16th. Mizuho set a $400.00 target price on Biogen and gave the stock a “buy” rating in a report on Thursday, January 18th. Jefferies Group reissued a “hold” rating on shares of Biogen in a report on Friday, January 26th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $279.00 target price on shares of Biogen in a report on Tuesday, October 24th. Eight equities research analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $368.99.
Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Thursday, January 25th. The biotechnology company reported $5.26 EPS for the quarter, missing the Zacks’ consensus estimate of $5.44 by ($0.18). The company had revenue of $3.31 billion during the quarter, compared to analyst estimates of $3.08 billion. Biogen had a net margin of 20.69% and a return on equity of 38.32%. The firm’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same period last year, the firm earned $5.04 EPS. equities analysts expect that Biogen will post 24.88 EPS for the current year.
In related news, CEO Michel Vounatsos purchased 780 shares of the company’s stock in a transaction that occurred on Friday, December 29th. The stock was acquired at an average price of $320.55 per share, with a total value of $250,029.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert W. Pangia sold 5,832 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $329.65, for a total value of $1,922,518.80. Following the completion of the transaction, the director now directly owns 23,539 shares of the company’s stock, valued at approximately $7,759,631.35. The disclosure for this sale can be found here. In the last ninety days, insiders purchased 31,560 shares of company stock valued at $10,020,858. 0.25% of the stock is owned by insiders.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.